Ketamine for Chronic
Inflammatory Pain in Baltimore
When the inflammation is controlled — and the pain still isn't
Ketamine for inflammatory pain in Baltimore is an off-label IV infusion — $1,499.99 per session, $1,125 for Vitality Circle members — evaluated for one specific thing: the central sensitization that persists after your rheumatologist has the inflammation under control. Every infusion is anesthesiologist-led care, under the medical direction of Dr. Brijen Joshi MD, a Johns Hopkins anesthesiologist, with a Certified Registered Nurse Anesthetist (CRNA) on-site. Chronic inflammatory cytokines — TNF-α, IL-1β, IL-6 — upregulate NMDA receptors in the spinal cord, and that amplification can outlive the disease activity that created it. Ketamine does not treat the inflammatory disease. It does not lower CRP or ESR, change disease activity scores, or replace DMARDs, biologics, or hydroxychloroquine — those must be optimized first, and your rheumatologist continues to manage them. For joint-specific disease, see ketamine for arthritis. Ketamine is off-label and results vary. $1,499.99/session non-member · $1,125/session Vitality Circle member.
Mon–Fri: 1PM–8PM · Sat: 10AM–2PM
513 Bayview Blvd, Canton, Baltimore MD 21224
(443) 563-1059
Tell Us About Your Situation
Answer a few quick questions — our clinical team reaches out within 1 business day to discuss whether ketamine therapy may be right for you.
Your information is confidential. A clinical team member follows up within 1 business day.
"My Biologic Is Working — My Rheumatologist Is Pleased. The Pain Hasn't Changed."
This is the clinical scenario that defines this page. A patient with ankylosing spondylitis whose CRP has normalized on a TNF inhibitor. A lupus patient whose SLEDAI score is controlled on hydroxychloroquine and belimumab. A psoriatic arthritis patient whose joint swelling has resolved. Their rheumatologist is satisfied with the disease control. And yet the widespread pain — the fatigue, the morning stiffness, the aching that pervades daily life — persists with barely any change.
Growing evidence in rheumatology is identifying this pattern as central sensitization — NMDA receptor hyperactivity in the spinal cord established by years of chronic inflammatory nociception that has become self-sustaining, generating and amplifying pain signals independently of the peripheral inflammatory process. Controlling the inflammation suppresses the peripheral driver. But it cannot reset the spinal cord that has spent years adapting to chronic inflammatory pain signals. That residual spinal cord mechanism is what ketamine targets on this page.
Chronic inflammatory arthritis of the spine and sacroiliac joints — producing morning stiffness, axial pain, and progressive spinal fusion over time. AS-associated central sensitization produces pain disproportionate to MRI inflammation, widespread mechanical allodynia, and fatigue not explained by disease activity scores.
Widespread pain exceeding spinal distribution · Pain persisting despite controlled BASDAI · Fatigue disproportionate to disease activity · Fibromyalgia-like features alongside AS
Inflammatory arthritis associated with psoriasis — affecting peripheral joints, spine, entheses, and skin. PsA produces significant pain burden through both active joint inflammation and, in chronic disease, established central sensitization. Pain in PsA is frequently disproportionate to joint swelling.
Widespread pain on DAS28 despite controlled inflammation · Enthesitis-like pain beyond active entheses · Fatigue and widespread sensitivity not matching joint count
Systemic autoimmune disease affecting multiple organ systems. SLE-related pain involves arthritis, serositis, and — particularly — central sensitization that produces widespread musculoskeletal pain even when organ-specific disease activity is controlled. Lupus fog overlaps with cognitive features of central sensitization.
Widespread pain with controlled SLEDAI · "Lupus fog" cognitive component · Pain and fatigue not correlating with inflammatory markers · Co-occurring fibromyalgia diagnosis
Inflammatory arthritis associated with Crohn's disease or ulcerative colitis. The NSAIDs that are first-line for most inflammatory arthritis are relatively contraindicated in IBD due to GI toxicity, limiting analgesia options. Biologics treat the IBD and arthropathy simultaneously, but central sensitization from chronic gut and joint inflammation may persist.
Widespread pain with controlled IBD · Pain persisting despite biologic response · Sensitization beyond joint distribution · Limited NSAID options making CS management options narrower
Inflammatory condition causing aching and stiffness in the shoulders, neck, upper arms, hips, and thighs — almost exclusively in adults over 50. PMR has a characteristic rapid and dramatic response to corticosteroids that is nearly diagnostic. However, patients with prolonged pre-diagnosis disease or incomplete steroid response may have established central sensitization.
Incomplete pain response despite adequate corticosteroid dosing · Pain persisting after inflammatory markers normalize · Prolonged symptom duration before diagnosis · Widespread distribution beyond typical PMR territory
FDA-Approved Disease-Modifying Treatments — The Most Extensive Landscape on the Pillar
Inflammatory rheumatological conditions have the most developed pharmacological treatment landscape of any conditions on the Vita Nova chronic pain pillar. These treatments must be optimized with your rheumatologist before ketamine evaluation. Ketamine is appropriate only when inflammatory disease is pharmacologically managed — not when inflammation is active and untreated.
These are not pain medications — they are disease-modifying agents that treat the underlying inflammatory condition. Ketamine at Vita Nova is evaluated only for patients whose rheumatological condition is pharmacologically managed but whose pain persists beyond current disease activity.
NSAIDs first (often significant relief in early AS), then biologics for inadequate NSAID responders
NSAIDs and conventional DMARDs (methotrexate, sulfasalazine) first, then biologics and targeted synthetic DMARDs
Hydroxychloroquine is prescribed for virtually every SLE patient as baseline therapy
Corticosteroids are first-line and typically produce rapid dramatic response — near-diagnostic
NSAIDs are largely contraindicated — biologics targeting both IBD and arthropathy are standard
- Treat ankylosing spondylitis, psoriatic arthritis, lupus, IBD arthropathy, or polymyalgia rheumatica as diseases
- Reduce CRP, ESR, IL-6, or any inflammatory marker
- Affect disease activity scores: BASDAI, ASDAS, DAS28, SLEDAI, or tender/swollen joint counts
- Replace, modify, or interact with DMARDs, biologics, hydroxychloroquine, or corticosteroids
- Substitute for rheumatological care — your rheumatologist manages the inflammatory disease. Vita Nova addresses the central sensitization component only
Inflammation → Central Sensitization → Pain That Outlasts the Disease
Understanding why pain persists in well-controlled inflammatory disease requires understanding the two-stage process through which chronic inflammation establishes central sensitization — and why suppressing the inflammation at stage one does not automatically reverse the central sensitization at stage two.
Active inflammatory disease generates continuous nociceptive input from inflamed joints, entheses, and soft tissues. Pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6) sensitize peripheral nociceptors at the site of inflammation — reducing their firing threshold and increasing the intensity of pain signals sent to the spinal cord.
Systemic and neuroinflammatory cytokines — particularly TNF-alpha, IL-1beta, and IL-17 — directly upregulate NMDA receptors in the spinal cord dorsal horn. This is not a consequence of peripheral nociception alone — it is a direct neuroinflammatory effect of the systemic cytokine milieu on spinal cord pain processing circuits. NMDA receptor upregulation lowers the spinal cord's threshold for pain amplification and initiates the wind-up mechanism that drives central sensitization.
After months to years of combined peripheral nociception and direct cytokine-mediated NMDA upregulation, the spinal cord's NMDA receptor hyperactivity becomes self-sustaining. The nervous system has undergone neuroplastic changes — long-term potentiation in pain processing circuits — that maintain central sensitization independently of ongoing peripheral inflammation or cytokine levels. Widespread pain, fatigue, allodynia, and pain disproportionate to disease activity are the clinical signatures.
TNF inhibitors, IL-17 inhibitors, JAK inhibitors, and hydroxychloroquine successfully suppress the peripheral inflammatory process — reducing joint swelling, normalizing CRP and ESR, improving disease activity scores. The peripheral driver of central sensitization is controlled. But the established spinal cord central sensitization does not automatically resolve — it has become neuroplastically independent of the peripheral inflammation that created it.
The patient whose rheumatologist is satisfied with their biologic response but whose widespread pain, fatigue, and allodynia are unchanged. The BASDAI that looks controlled while the patient is barely functional. This is central sensitization sustaining pain independently of inflammation. DMARDs and biologics address the peripheral driver; they cannot reset the spinal cord that has been sensitized for years.
Ketamine's NMDA receptor blockade directly targets the spinal cord hyperexcitability sustaining central sensitization after inflammatory control — the specific mechanism that biologics and DMARDs cannot reach. A series of infusions may allow the spinal cord to reset toward normal excitability thresholds — reducing the widespread pain, allodynia, and disproportionate pain amplification that persists despite excellent rheumatological disease management.
Polymyalgia Rheumatica — When Corticosteroids Work and Then Don't
PMR occupies a distinctive position on this page because its treatment response is so characteristic — and because understanding why some PMR patients develop refractory pain despite adequate corticosteroid treatment reveals the central sensitization mechanism with particular clarity.
PMR is famous for its corticosteroid response: most patients experience dramatic — sometimes complete — pain relief within 24–72 hours of starting prednisone. This rapid, profound response is so characteristic that it functions almost as a diagnostic criterion. The corticosteroid suppresses the inflammatory process driving the proximal girdle pain.
So why are some PMR patients still significantly painful despite adequate corticosteroid dosing and normalized CRP? Several possibilities: prolonged pre-diagnosis disease during which central sensitization became established; incomplete CS resolution despite inflammatory control; long-term corticosteroid side effects limiting adequate dosing. For this subset, the residual pain is increasingly recognized as central sensitization — not residual inflammation.
A patient with classic PMR started on prednisone 15–20mg: shoulders, neck, and hips rapidly improve within days. CRP and ESR normalize within weeks. As the prednisone is tapered, widespread aching and stiffness return at doses below 10mg. When inflammatory markers remain controlled at this pain level, the pain is increasingly likely to represent established central sensitization rather than active inflammation. This is the scenario where ketamine evaluation becomes appropriate — not to replace corticosteroids, but to address the CS component that persists alongside managed inflammation.
Ketamine at Vita Nova is evaluated for PMR patients whose inflammatory markers are controlled on corticosteroids (or tocilizumab) but whose pain remains disproportionate to current disease activity. The rheumatologist manages the inflammatory PMR — Vita Nova targets the central sensitization component that corticosteroids cannot reach. Coordination with the prescribing rheumatologist is essential — corticosteroid management decisions are made by the rheumatologist, not by Vita Nova.
Fibromyalgia Co-Occurring With Inflammatory Disease — The Same NMDA Mechanism
The extraordinarily high co-occurrence of fibromyalgia in inflammatory rheumatological conditions is not coincidental — it reflects the same NMDA-mediated spinal cord mechanism viewed through two different diagnostic lenses. The central sensitization produced by years of chronic inflammatory nociception is mechanistically identical to the central sensitization of primary fibromyalgia — NMDA receptor hyperactivity in the dorsal horn, lowered pain thresholds, widespread amplification, allodynia, and fatigue. Whether the patient receives a fibromyalgia diagnosis alongside their AS or whether their rheumatologist attributes the widespread pain to "inflammatory pain," the spinal cord mechanism is the same.
Clinically, this matters for ketamine evaluation: a PsA patient with widespread pain, fatigue, and allodynia that doesn't track their joint count may never receive a fibromyalgia co-diagnosis — but their central sensitization is just as real and just as NMDA-driven as a patient with primary fibromyalgia. Ketamine's NMDA blockade addresses the central sensitization mechanism regardless of the diagnostic label applied to it.
Learn More About Fibromyalgia & Ketamine →Inflammatory Pain Pricing at Vita Nova
| Service | Non-Member | Vitality Circle Member | Saving |
|---|---|---|---|
| Ketamine — Chronic Pain / session Off-Label | $1,499.99 | $1,125 | $374.99/session |
Depression and anxiety co-occur in 30–50% of inflammatory rheumatological conditions. Treating a documented co-occurring mental health condition may additionally reduce pain through improved descending pain inhibition — which is why a single evaluation considers your whole pain picture. See our co-occurring depression & chronic pain page.
Self-pay, with a superbill. Every session is anesthesiologist-led care, under the medical direction of Dr. Brijen Joshi MD — Johns Hopkins faculty — in a private treatment room with continuous cardiac and vital-sign monitoring, with a Certified Registered Nurse Anesthetist (CRNA) on-site. Vita Nova is self-pay for ketamine and provides an itemized superbill you can submit to your insurance plan (see our ketamine insurance guide). HSA and FSA accepted; Community Heroes discounts available. Vitality Circle membership ($99.99/month) pays for itself on a single session — the member rate saves $374.99, more than the membership. Sessions determined individually — first visit? Read the new patient guide.
HSA and FSA accepted. Community Heroes discounts available. Rheumatologist coordination encouraged. Pricing August 2026 — subject to change. Full pricing guide →
Complementary Treatments Supporting Inflammatory Pain Relief
Several wellness services at Vita Nova address physiological factors relevant to inflammatory pain. Always discuss with your rheumatologist before beginning.
The most relevant wellness service for inflammatory pain. High-dose IV Vitamin C directly addresses oxidative stress and inflammatory cytokine load — the peripheral inflammatory component that drives and maintains central sensitization. Vitamin C has antioxidant properties relevant to the reactive oxygen species produced by chronic inflammatory disease.
Members: 25% offIron-deficiency anemia is common in inflammatory disease — especially IBD-related arthropathy, where chronic gut inflammation and blood loss deplete iron and oral supplements are often poorly tolerated. Anemia of chronic disease compounds the fatigue these conditions already cause. When bloodwork confirms iron-deficiency anemia, IV iron restores stores faster than oral iron many patients cannot absorb or tolerate.
Members: 25% offMagnesium modulates NMDA receptor sensitivity directly relevant to ketamine's central sensitization mechanism. Magnesium deficiency is common in inflammatory conditions — worsened by chronic corticosteroid use (which depletes magnesium through urinary losses) in PMR and SLE patients. Restoring magnesium provides complementary NMDA-modulating support.
Members: Included (2 shots/month)Methotrexate (used in PsA and RA) depletes folate and B12 — contributing to fatigue, mood changes, and neuropathic symptoms that overlap with central sensitization features. Hydroxychloroquine in SLE patients is associated with B vitamin interactions. B12 and B-Complex shots address these depletion effects relevant to the co-occurring mood and neuropathic components of inflammatory disease pain.
Members: Included (2 shots/month)Mitochondrial dysfunction is increasingly documented in autoimmune and inflammatory conditions — particularly SLE and inflammatory arthritis. Chronic inflammation and long-term immunosuppressive medications deplete NAD+ reserves, contributing to the profound fatigue that characterizes these conditions beyond pain alone. NAD+ IV Therapy supports mitochondrial energy restoration relevant to the fatigue component.
Members: 25% off all dosesCritical note: All wellness services must be discussed with your rheumatologist before beginning — particularly Vitamin C IV (relevant interactions with methotrexate and other immunosuppressants), magnesium (corticosteroid interactions), and B-Complex (methotrexate folate interactions). These are wellness services, not treatments for inflammatory disease, and do not replace rheumatological management.
Special Pricing for Those Who Serve
Veterans and active-duty service members carry elevated rates of ankylosing spondylitis, inflammatory arthritis, and autoimmune conditions — many diagnosed late after years of pain attributed to occupational injury rather than systemic inflammatory disease.
Inflammatory Pain & Ketamine — Questions Answered
Real, high-intent questions from patients with inflammatory conditions evaluating ketamine and IV therapy in Baltimore.
Your Rheumatologist Controls
the Inflammation. We Target What Remains —
When biologic response is documented and CRP is normal but widespread pain persists — that residual pain is increasingly recognized as central sensitization, not residual inflammation. Ketamine's NMDA mechanism reaches the spinal cord amplification that disease-modifying therapy cannot. Rheumatologist coordination encouraged. Community Heroes discounts available.
Medically reviewed by Dr. Brijen L. Joshi, MD — Founder & Medical Director, Johns Hopkins Assistant Professor of Anesthesiology & Critical Care Medicine.
Canonical URL: https://vitanovawellnessclinic.com/ketamine-inflammatory-pain-baltimore/ · Last reviewed August 2026
